Slide 1: Higher sales, improved margins and launches that bring high customer value
Higher sales, improved margins and launches that bring high customer value Getinge Q2 2024 Mattias Perjos, CEO Agneta Palmér, CFO
Slide 2: Key takeaways
Key takeaways Q2 2024 • Net sales increased by 15.7% whereof 8.9% organically and order intake grew by 14.4% whereof 7.8% organically • Margins positively impacted by volume, product mix and price realizations • The financial position remains solid 33,328 34,000 55 16 32,000 49.5 14 12.7 50 0 0 Q2 2
Slide 3: Key activities and events
Key activities and events Q2 2024 Offering and customers Updated financial target • Launched Poladus 150, an advanced • Average annual growth in adjusted low-temperature sterilizer EPS: >12% 2024-2028 • 510(k) clearance for Talis Advanced Sustainability and Quality Clinical Guidance • Accelerated th
Slide 4: Organic sales and order growth by region
Organic sales growth in all regions thanks to Acute Care Therapies Soft organic order intake in Americas due to Surgical Workflows and Life Science Global Americas EMEA APAC +7.8% Organic Order Growth +8.9% Organic Net Sales Growth Getinge │ Presentation │ Q2 Report 2024 July 18, 2024
Slide 5: Outlook 2024
Outlook 2024 Net sales for 2024 expected to increase by 2-5% organically (unchanged) Getinge │ Presentation │ Q2 Report 2024 July 18, 2024
Slide 6: Organic order growth in all business areas
Organic order growth in all business areas Order Intake Bridge Q2 2023 – Q2 2024 Organic change +8.0% +18.4% +3.4% +7.8% +14.4% 460 281 318 8,414 7,356 MSEK Q2 2023 Acute Care Therapies Life Science Surgical Workflows Q2 2024 Getinge │ Presentation │ Q2 Report 2024 July 18, 2024
Slide 7: Strong sales growth in Acute Care Therapies vs last year's low comps
Strong sales growth in Acute Care Therapies vs last year’s low comps Net Sales Bridge Q2 2023 – Q2 2024 Organic change +23.2% -13.1% -2.2% +8.9% +15.7% 318 -5 830 Currency impact, MSEK -19 15.5 8,305 MSEK 7,176 Organic growth, % Q2 2023 Acute Care Life Science Surgical Q2 2024 -1.7 Therapies Workflo
Slide 8: Adj Gross Margin increased in all business areas versus last year
Adj Gross Margin increased in all business areas versus last year Adjusted Gross Profit Bridge Q2 2023 – Q2 2024 Adj GM, % Q2 2024 58.7 37.9 40.9 50.0 (Q2 2023) (55.1) (35.1) (38.1) (46.2) Gross Margin impact +25.3% 24 200 614 Product and Geo mix Cost inflation 4,151 Price MSEK 3,314 Currency Q2 202
Slide 9: Adj EBITA margin increased versus last year's low comp
Adj EBITA margin increased versus last year’s low comp Adjusted EBITA Bridge Q2 2023 – Q2 2024 11.8% Margin development 6.9% +3.3 pp Adj GP +486 +1.0 pp Adj OPEX 837 +0.5 pp D&A +0.1 pp FX -174 33 -99 -83 -27 +11 Currency impact, MSEK 981 MSEK 495 Q2 2023 Adj Gross Adj Selling Adj Admin Adj R&D Othe
Slide 10: Stable Free Cash Flow and Working Capital days trending down
Stable Free Cash Flow and Working Capital days trending down Capital efficiency a priority Positive Free Cash Flow WC days below 100 ROIC below trend, but still well above pre-pandemic levels 97 96 95 94 1.1 93 1.0 0.9 92 11.1% 91 7.5% 0.3 0.3 0 Q2 2019 Q2 2020 Q2 2021 Q2 2022 Q2 2023 Q2 2024 Q2 202
Slide 11: Solid financial position
Solid financial position Recent acquisitions impacting net debt, but financial position is strong Net debt increased due to acquisitions … … but leverage is way below 2.5x 9.0 8.0 7.6 1.4 1.4 1.5 5.0 3.8 0.9 (6.3 BSEK excl. pension 0.7 (1.1x excl. liabilities) 1.5 pension liabilities) Q2 2023 Q3 202
Slide 12: Summary
Summary Getinge │ Presentation │ Q2 Report 2024 July 18, 2024
Slide 13: Key takeaways
Key takeaways Summary Q2 2024 • Strong growth in net sales and orders • Improved margins • Solid financial position Getinge │ Presentation │ Q2 Report 2024 July 18, 2024
Slide 14: Q&A
Q&A Getinge │ Presentation │ Q2 Report 2024 July 18, 2024
Slide 15: Thank you
Thank you Getinge │ Presentation │ Q2 Report 2024 July 18, 2024
Slide 16: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 17: Getinge - Passion for Life
“= Se A GETINGE PASSION FOR LIFE